title: Survival after the diagnosis of hyperparathyroidism: a population-based study.
abstract: BACKGROUND
  Reports of increased mortality from cardiovascular disease and malignancy in primary hyperparathyroidism have been based primarily on patients who have undergone parathyroidectomy. In order to assess the true impact of primary hyperthyroidism on mortality in the general population, we assessed survival in a large inception cohort of Rochester, Minnesota residents with primary hyperparathyroidism initially diagnosed over a 28-year span, the majority of whom were followed with uncomplicated disease.
  
  
  METHODS
  All Rochester residents with primary hyperparathyroidism first recognized in 1965 to 1992 were identified through the Rochester Epidemiology Project medical records linkage system. Included as cases were patients with pathologic confirmation of hyperthyroidism, hypercalcemia with inappropriately elevated parathyroid hormone levels, or hypercalcemia for more than a year with no other cause. Survival was estimated using the Kaplan Meier product-limit method. The Cox proportional hazards model was used to determine associations, as relative hazards (RR) with 95% confidence intervals (CI), of various risk factors with time to death.
  
  
  RESULTS
  During the study period, 435 cases of primary hyperparathyroidism were identified. Altogether, parathyroid surgery was performed on 126 patients (29%), with a mean delay between the initial elevated serum calcium level and surgery of 3.3 years. Patients who underwent surgery had higher maximum serum calcium levels than the patients who were observed (mean+/-SD, 11.3+/-0.7 versus 10.7+/-0.4 mg/dL, P <0.00 1), but their mean ages were similar (54+/-16 versus 56+/-17 years). Overall survival in the patients with primary hyperthyroidism was better than expected (P=0.02), but by age-adjusted multivariate analysis, higher maximal serum calcium level was an independent predictor of mortality (RR=1.3 per mg/dL; 95% CI: 1.1-1.6; P <0.02).
  
  
  CONCLUSIONS
  Overall survival is not adversely affected among unselected patients with mild primary HPT in the community, although patients with more severe disease, as manifested by higher serum calcium levels, may have an increased risk of death.
authors.affiliation: Division of Endocrinology/Metabolic Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Wermers
authors.forename: S
authors.initials: S
authors.lastname: Khosla
authors.forename: E J
authors.initials: EJ
authors.lastname: Atkinson
authors.forename: C S
authors.initials: CS
authors.lastname: Grant
authors.forename: S F
authors.initials: SF
authors.lastname: Hodgson
authors.forename: W M
authors.initials: WM
authors.lastname: O'Fallon
authors.forename: L J
authors.initials: LJ
authors.lastname: Melton
mesh_terms: D002118:Calcium / Q000097:blood; D002423:Cause of Death; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000175:diagnosis / Q000401:mortality* / Q000601:surgery; D008910:Minnesota / Q000453:epidemiology; D010281:Parathyroid Hormone / Q000097:blood; D011159:Population Surveillance; D012306:Risk; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D010281:Parathyroid Hormone; D002118:Calcium